Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome.

Autor: Borja MS; Children's Hospital Oakland Research Institute, Oakland, California, United States of America.; Department of Chemistry and Biochemistry, California State University East Bay, Hayward, California, United States of America., Hammerson B; Children's Hospital Oakland Research Institute, Oakland, California, United States of America., Tang C; University of Washington School of Medicine, Seattle, Washington, United States of America., Juarez-Serrano L; Department of Chemistry and Biochemistry, California State University East Bay, Hayward, California, United States of America., Savinova OV; Cardiovascular Research Center, Sanford Research, University of South Dakota, Sioux Falls, South Dakota, United States of America., Harris WS; Cardiovascular Research Center, Sanford Research, University of South Dakota, Sioux Falls, South Dakota, United States of America.; OmegaQuant, Sioux Falls, South Dakota, United States of America., Oda MN; Children's Hospital Oakland Research Institute, Oakland, California, United States of America., Shearer GC; Cardiovascular Research Center, Sanford Research, University of South Dakota, Sioux Falls, South Dakota, United States of America.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2024 Feb 26; Vol. 19 (2), pp. e0296052. Date of Electronic Publication: 2024 Feb 26 (Print Publication: 2024).
DOI: 10.1371/journal.pone.0296052
Abstrakt: HDL-apolipoprotein A-I exchange (HAE) measures a functional property associated with HDL's ability to mediate reverse cholesterol transport. HAE has been used to examine HDL function in case-control studies but not in studies of therapeutics that alter HDL particle composition. This study investigates whether niacin and omega-3 fatty acids induce measurable changes in HAE using a cohort of fifty-six subjects with metabolic syndrome (MetS) who were previously recruited to a double-blind trial where they were randomized to 16 weeks of treatment with dual placebo, extended-release niacin (ERN, 2g/day), prescription omega-3 ethyl esters (P-OM3, 4g/day), or the combination. HAE was assessed at the beginning and end of the study. Compared to placebo, ERN and P-OM3 alone significantly increased HAE by 15.1% [8.2, 22.0] (P<0.0001) and 11.1% [4.5, 17.7] (P<0.0005), respectively, while in combination they increased HAE by 10.0% [2.5, 15.8] (P = 0.005). When HAE was evaluated per unit mass of apoA-I ERN increased apoA-I specific exchange activity by 20% (2, 41 CI, P = 0.02) and P-OM3 by 28% (9.6, 48 CI, P<0.0006). However the combination had no statistically significant effect, 10% (-9, 31 CI, P = 0.39). With regard to P-OM3 therapy in particular, the HAE assay detected an increase in this property in the absence of a concomitant rise in HDL-C and apoA-I levels, suggesting that the assay can detect functional changes in HDL that occur in the absence of traditional biomarkers.
Competing Interests: MNO has an affiliation with Seer Biologics, Inc. MNO is a founder of and owns a significant stake in Seer Biologics, Inc., which could stand to benefit from the research described here. This in no way influenced the thoroughness, stringency, interpretation and presentation of this manuscript’s content. This affiliation does not alter the author’s adherence to PLOS ONE policies on sharing data and materials. At the time of the parent study, GCS was supported by GlaxSmithKline. The other authors declare no competing interests.
(Copyright: © 2024 Borja et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje